HCA Healthcare Inc banner

HCA Healthcare Inc
LSE:0J1R

Watchlist Manager
HCA Healthcare Inc Logo
HCA Healthcare Inc
LSE:0J1R
Watchlist
Price: 397.7 USD -3.63% Market Closed
Market Cap: $136.9B

Wall St Price Targets

0J1R Price Targets Summary
HCA Healthcare Inc

Wall Street analysts forecast 0J1R stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0J1R is 504.19 USD with a low forecast of 374.7 USD and a high forecast of 662.79 USD.

Lowest Forecast
Price Target
374.7 USD
6% Downside
Average Forecast
Price Target
504.19 USD
27% Upside
Highest Forecast
Price Target
662.79 USD
67% Upside
HCA Healthcare Inc Competitors:
Price Targets
FILA
FILA Fabbrica Italiana Lapis ed Affini SpA
43% Upside
NTHI
NeOnc Technologies Holdings Inc
366% Upside

Revenue
Forecast

7% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
7% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 6%.

Gross Profit
Forecast

7% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
54%
Average Beat
7% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
54%
Average Beat

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 8 years is -4%.

Operating Income
Forecast

7% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
7% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 8 years is 4%.

Pre-Tax Income
Forecast

10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
10% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 3%.

Net Income
Forecast

12% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
12% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 5%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0J1R's stock price target?
Price Target
504.19 USD

According to Wall Street analysts, the average 1-year price target for 0J1R is 504.19 USD with a low forecast of 374.7 USD and a high forecast of 662.79 USD.

What is the Revenue forecast for HCA Healthcare Inc?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 6%.

What is the Gross Profit forecast for HCA Healthcare Inc?
Projected CAGR
-4%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 8 years is -4%.

What is the Operating Income forecast for HCA Healthcare Inc?
Projected CAGR
4%

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 8 years is 4%.

What is the Pre-Tax Income forecast for HCA Healthcare Inc?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 3%.

What is the Net Income forecast for HCA Healthcare Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 5%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett